OMB OKs Quantitative Claims Survey for DTC Ads

Federal Register notice: FDA is announcing that OMB has approved an information collection entitled “Survey on Quantitative Claims in Direct-to-Consumer Prescription Drug Advertising.” This type of (XXX SUBSTITUTE XXX)advertising may make quantitative claims about a drug’s efficacy or risks, and the agency has research and guidance available that provides general guidelines on how to present such information, but it says it is not fully understood how consumers will interpret specific quantitative claims. FDA says the survey is intended to answer how consumers interpret different claims describing medians (e.g., “People treated with Drug X lived for a median of eight months.” It also contains questions about respondents’ perceptions and understanding of several quantitative claims drawn from DTC ads in the marketplace. “We will also measure other potentially important variables, such as demographics and numeracy,” the agency says. To view the notice, click here.